Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Effect of posaconazole on cyclosporine blood levels and dose adjustment in allogeneic blood and marrow transplant recipients.

Sánchez-Ortega I, Vázquez L, Montes C, Patiño B, Arnan M, Bermúdez A, Yáñez L, Caballero T, Duarte RF.

Antimicrob Agents Chemother. 2012 Dec;56(12):6422-4. doi: 10.1128/AAC.01489-12. Epub 2012 Oct 1.

2.

Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus.

Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG.

Pharmacotherapy. 2007 Jun;27(6):825-34.

PMID:
17542765
3.

Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation.

Kohl V, Müller C, Cornely OA, Abduljalil K, Fuhr U, Vehreschild JJ, Scheid C, Hallek M, Rüping MJ.

Antimicrob Agents Chemother. 2010 Jan;54(1):207-12. doi: 10.1128/AAC.01027-09. Epub 2009 Oct 26.

4.

Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients.

Mori T, Aisa Y, Kato J, Nakamura Y, Ikeda Y, Okamoto S.

Bone Marrow Transplant. 2009 Sep;44(6):371-4. doi: 10.1038/bmt.2009.38. Epub 2009 Mar 9.

PMID:
19270729
5.

Adverse drug interactions as a high-risk factor for lethal post-transplant complications in Chinese population.

Yang T, Wu XM, Qiu HQ, Fu DH, Hu JD, Li J, Zheng XY, Luo XF, Yuan XH, Chen RL, Chen ZZ.

Clin Transplant. 2013 Mar-Apr;27(2):255-60. doi: 10.1111/ctr.12070. Epub 2013 Jan 7.

PMID:
23294039
6.

Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients.

Winston DJ, Bartoni K, Territo MC, Schiller GJ.

Biol Blood Marrow Transplant. 2011 Apr;17(4):507-15. doi: 10.1016/j.bbmt.2010.04.017. Epub 2010 May 9.

7.

Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation.

Groll AH, Kolve H, Ehlert K, Paulussen M, Vormoor J.

J Antimicrob Chemother. 2004 Jan;53(1):113-4. Epub 2003 Dec 4.

PMID:
14657088
8.

Management of drug interaction between posaconazole and sirolimus in patients who undergo hematopoietic stem cell transplant.

Cho E, Chan H, Nguyen HM, Shayani S, Nakamura R, Pon D.

Pharmacotherapy. 2015 Jun;35(6):578-85. doi: 10.1002/phar.1600. Epub 2015 Jun 3.

PMID:
26037821
9.

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D.

N Engl J Med. 2007 Jan 25;356(4):348-59.

10.

Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.

Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H.

Pharmacotherapy. 2007 Dec;27(12):1627-36.

PMID:
18041883
11.

Optimal blood concentration of cyclosporine among Iranian kidney transplant recipients.

Rostami Z, Einollahi B, Morshedi J, Teimoori M.

Iran J Kidney Dis. 2012 Sep;6(5):373-9. Erratum in: Iran J Kidney Dis. 2012 Nov;6(6):472. Morshedi, Jamileh [added].

12.

Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience.

Girmenia C, Frustaci AM, Gentile G, Minotti C, Cartoni C, Capria S, Trisolini SM, Matturro A, Loglisci G, Latagliata R, Breccia M, Meloni G, Alimena G, Foà R, Micozzi A.

Haematologica. 2012 Apr;97(4):560-7. doi: 10.3324/haematol.2011.053058. Epub 2011 Nov 18.

13.

Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.

Yasu T, Konuma T, Kato S, Kurokawa Y, Takahashi S, Tojo A.

Ann Hematol. 2016 Oct;95(11):1845-51. doi: 10.1007/s00277-016-2782-z. Epub 2016 Aug 18.

PMID:
27535751
14.

Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.

Krishna G, AbuTarif M, Xuan F, Martinho M, Angulo D, Cornely OA.

Pharmacotherapy. 2008 Oct;28(10):1223-32. doi: 10.1592/phco.28.10.1223.

PMID:
18823218
15.

Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.

Berge M, Guillemain R, Boussaud V, Pham MH, Chevalier P, Batisse A, Amrein C, Dannaoui E, Loriot MA, Lillo-Le Louet A, Billaud EM.

Transpl Infect Dis. 2009 Jun;11(3):211-9. doi: 10.1111/j.1399-3062.2009.00384.x. Epub 2009 Mar 17.

PMID:
19302272
16.

Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation.

Döring M, Müller C, Johann PD, Erbacher A, Kimmig A, Schwarze CP, Lang P, Handgretinger R, Müller I.

BMC Infect Dis. 2012 Oct 19;12:263. doi: 10.1186/1471-2334-12-263.

17.

Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.

Ananda-Rajah MR, Grigg A, Downey MT, Bajel A, Spelman T, Cheng A, Thursky KT, Vincent J, Slavin MA.

Haematologica. 2012 Mar;97(3):459-63. doi: 10.3324/haematol.2011.051995. Epub 2011 Nov 4.

18.

[Immunosuppressive-associated encephalopathy in bone marrow transplant recipients].

Ohta K, Yoritaka A, Sakamaki H, Kishida S; Bone Marrow Transplantation Group.

No To Shinkei. 2004 May;56(5):395-401. Japanese.

PMID:
15279197
19.

Cyclosporine alone vs cyclosporine plus methotrexate for post-transplant immunosuppression after HLA-identical sibling bone marrow transplantation: a randomized prospective study.

Lee KH, Choi SJ, Lee JH, Kim S, Seol M, Lee YS, Kim WK, Lee JS, Lee JH.

Bone Marrow Transplant. 2004 Oct;34(7):627-36.

PMID:
15300231
20.

[The latest data on posaconazole].

Paugam A.

Med Mal Infect. 2007 Feb;37(2):71-6. Epub 2007 Jan 30. Review. French.

PMID:
17267154

Supplemental Content

Support Center